Hormel Foods vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Austin MN branded food (NYSE: HRL) ~$11.9B FY2024 revenue; SPAM/Skippy/Planters/Jennie-O portfolio, 250-position restructuring 2025, Planters $3.35B integration challenge competing with Tyson and Conagra.
About
Hormel Foods Corporation is an Austin, Minnesota-based multinational food company — publicly traded on the New York Stock Exchange (NYSE: HRL) as an S&P 500 Consumer Staples component — producing, marketing, and distributing branded consumer food products across refrigerated, shelf-stable, and deli categories under the Hormel, SPAM, Jennie-O, Skippy, Planters, Columbus Craft Meats, Applegate, Justin's, Natural Choice, and Wholly brands through approximately 20,000 employees serving customers across 80+ countries. In fiscal year 2024 (ending October 2024), Hormel reported revenue of approximately $11.9 billion, with performance reflecting challenges in the turkey market (Jennie-O facing supply and competitive dynamics), commodity cost management, and ongoing integration of the Planters snack nuts business (acquired from Kraft Heinz in 2021 for $3.35 billion). Hormel announced a comprehensive corporate restructuring in 2025 — including a voluntary early retirement program and the elimination of approximately 250 corporate and sales positions — targeting $20-25 million in restructuring charges as the company streamlines operations to improve efficiency and align resources with strategic priorities following the Planters acquisition integration challenge. CEO Jim Snee leads Hormel's "Transform and Modernize" strategy focusing on operational efficiency, brand investment, and portfolio optimization. The Planters acquisition (peanuts, cashews, mixed nuts, peanut butter, Cheez Balls) gave Hormel a leading position in the $8B+ US nut snack market but has required margin improvement work.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.